Prostate Cancer

Results from the ARASENS trials demonstrate superior survival outcomes with darolutamide versus placebo plus androgen deprivation therapy and docetaxel.

A significant percentage of reduction in the risk of radiographic disease progression or death was observed with olaparib plus abiraterone compared with placebo and abiraterone in patients with metastatic castration resistant prostate cancer.

Phase 3 MAGNITUDE study results show positive efficacy for niraparib plus abiraterone in HRR gene-altered metastatic castration resistant prostate cancer.

A look back at apalutamide treatment in the the TITAN and SPARTAN trials showed that deep prostate-specific antigen responses lead to improvement in certain health-related quality of life factors.

According to real-world data, apalutamide may be more likely to offer an early and deep prostate-specific antigen reduction than enzalutamide.

In an interview with Targeted Oncology, Bridget Koontz, MD, United States chief medical officer and deputy global chief medical officer at GenesisCare, discusses 18F-DCFPyL and how the well-tolerated agent can change the way prostate cancer patients are treated

In an interview with Targeted Oncology, Neal Shore discusses the findings of ARAMIS which looked at darolutamide in men with high-risk non-metastatic castration-resistant prostate cancer, and its primary end point of metastasis-free survival.

During a Targeted Oncology live event, Jahan Aghalar, MD, and Daniel Vaena, MD, discussed the results of trials of cabazitaxel in patients with castration-resistant prostate cancer and how to manage toxicity of the therapy.

Current findings validate and support the clinical utility of enzalutamide regardless of metastatic burden or type of oligometastatic disease, according to the investigators.

Dan Petrylak, MD, discusses the pros and cons of using abiraterone as a front-line therapy for mCSPC and provides details of the PEACE-1 study.

Dr Petrylak presents our second case, a 62-year-old man with mCSPC.

An expert explains the unmet needs in the mCSPC landscape, as well as key takeaways if you are treating patients with this disease.

Dr Petrylak recalls the study design and results of the TITAN study.

Dan Petrylak, MD, presents our first case for discussion, an 80-year-old man with metastatic castration-sensitive prostate cancer (mCSPC). Front-line therapy options and monitoring for mCSPC are also mentioned.

Daniel P. Petrylak, MD, discusses the design and results of the TITAN trial of apalutamide in patients with metastatic castration-sensitive prostate cancer.

The improvement in detection and treatment associated with PSMA cannot be overstated, with many investigators describing the advancement as a global practice changer.

Dr. Bobby Liaw looks to the future of metastatic castration-sensitive prostate cancer treatment and provides some advice and clinical pearls.

A key opinion leader reviews how findings from the TITAN study affect treatment of metastatic castration-sensitive prostate cancer.

Bobby Liaw, MD, explains the potential treatment strategy for a prostate cancer case with low-volume metastatic disease.

A prostate cancer expert reviews the treatment approach in the presented case of biochemical recurrence of prostate cancer with high-volume castration-sensitive metastatic disease.

Dr. Bobby Liaw compares the available first-line therapy options for metastatic castration-sensitive prostate cancer and explains how to decide on a therapy.

An oncologist details the first-line therapy options for metastatic castration-sensitive prostate cancer.

Bobby Liaw, MD, presents the case of a 73-year-old man with biochemical recurrence of prostate cancer and metastatic castration-sensitive high-volume disease.

Survival benefit was shown with the combination of niraparib and rucaparib in patients with chemotherapy-naive metastatic castration-resistant prostate cancer.

During a conference presentation, A. Oliver Sartor, MD, explained how researchers are building upon the principles of T-cell redirecting agents, such as bispecific T-cell engagers, from other cancer types for the sake of treating patients with prostate cancer.

According to Ajjai S. Alva, MBBS, CDK12 is a cell cycle gene that has an important role in RNA polymerase 2 and immunotherapy activity.

During a live virtual event, Eleni Efstathiou, MD, PhD, discussed the phase 3 PROSPER trial of enzalutamide and the phase 3 ARAMIS trial of darolutamide in patients with castration-resistant prostate cancer.

Six months after a 75-year-old patient with castration-resistant prostate cancer shows undetectable PSA, the patient developed new hip pain and urinary frequency.

Daniel P. Petrylak, MD, discusses the impact of the approval of apalutamide in the metastatic castration-sensitive prostate cancer setting.

During a live virtual event, Eleni Efstathiou, MD, PhD, discussed the phase 3 SPARTAN trial of apalutamide in patients with castration-resistant prostate cancer.